Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial

The Journal of Infectious Diseases
Khalequ ZamanKathleen M Neuzil

Abstract

The burden of rotavirus morbidity and mortality is high in children aged <5 years in developing countries, and evaluations indicate waning protection from rotavirus immunization in the second year. An additional dose of rotavirus vaccine may enhance the immune response and lengthen the period of protection against disease, but coadministration of this dose should not interfere with immune responses to concurrently given vaccines. A total of 480 9-month-old participants from Matlab, Bangladesh, were enrolled in a study with a primary objective to establish noninferiority of concomitant administration of measles-rubella vaccine (MR) and a third dose of human rotavirus vaccine (HRV; MR + HRV), compared with MR given alone. Secondary objectives included noninferiority of rubella antibody seroconversion and evaluating rotavirus IgA/IgG seroresponses in MR + HRV recipients. Two months after vaccination, 75.3% and 74.3% of MR + HRV and MR recipients, respectively, had seroprotective levels of measles virus antibodies; 100.0% and 99.6%, respectively, showed anti-rubella virus immunoglobulin G (IgG) seroprotection. In the MR + HRV group, antirotavirus immunoglobulin A and IgG seropositivity frequencies before vaccination (52.7% and 66.3...Continue Reading

References

Jun 1, 1991·Journal of Virological Methods·D R KnowltonR L Ward
Nov 1, 1990·The Journal of Infectious Diseases·R T ChenW A Orenstein
Jan 1, 1989·The Journal of Infectious Diseases·R L WardG M Schiff
May 1, 1983·Infection and Immunity·G P DavidsonC P Kirubakaran
Jan 1, 1995·The Pediatric Infectious Disease Journal·M M CarsonH F Pabst
Mar 6, 1999·Clinical and Diagnostic Laboratory Immunology·R F HelfandW J Bellini
Jun 4, 2005·The Pediatric Infectious Disease Journal·Penelope H DennehyUNKNOWN North American Human Rotavirus Vaccine Study Group
Feb 7, 2007·Expert Review of Vaccines·Miguel O'Ryan
Mar 21, 2007·Emerging Infectious Diseases·Mustafizur RahmanTasnim Azim
Dec 8, 2007·Vaccine·Bernard J CohenUNKNOWN WHO working group on measles plaque reduction neutralization test
Aug 30, 2008·The Pediatric Infectious Disease Journal·Max CiarletFlorian Schödel
Jun 6, 2009·JAMA : the Journal of the American Medical Association·Manish PatelUmesh Parashar
Oct 30, 2009·Expert Review of Vaccines·Manish M PatelUmesh D Parashar
Jan 29, 2010·The New England Journal of Medicine·Shabir A MadhiKathleen M Neuzil
Jun 17, 2010·BMJ : British Medical Journal·Orbelina de PalmaManish Patel
Jun 7, 2011·Vaccine·Juliana Romualdo Nascimento SilvaUNKNOWN Collaborative Group for the Study of Yellow Fever Vaccines
Jun 17, 2011·The New England Journal of Medicine·Manish M PatelUmesh D Parashar
Dec 17, 2011·The Pediatric Infectious Disease Journal·Jeanne LoughlinJohn D Seeger
Jun 9, 2012·Current Opinion in Virology·Juana AngelHarry B Greenberg
Jun 21, 2013·BMJ : British Medical Journal·Manish M PatelLucia Helena De Oliveira
Jul 13, 2014·Virus Research·Ulrich Desselberger

❮ Previous
Next ❯

Citations

Jan 30, 2016·The Journal of Infectious Diseases·Nigel Cunliffe, Gagandeep Kang
Jun 3, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James A Platts-MillsEric R Houpt
Nov 17, 2016·Clinical and Vaccine Immunology : CVI·Katayi MwilaSylvia Becker-Dreps
Feb 2, 2018·Paediatric Drugs·Eleanor BurnettJacqueline Tate
Feb 9, 2019·Human Vaccines & Immunotherapeutics·A D SteeleC D Kirkwood
Mar 27, 2019·The Cochrane Database of Systematic Reviews·Karla Soares-WeiserNigel Cunliffe
Nov 7, 2019·The Cochrane Database of Systematic Reviews·Karla Soares-WeiserNigel Cunliffe
Dec 24, 2019·Salud pública de México·Umesh D Parashar, Jacqueline E Tate
Jul 2, 2020·Vaccines·Olufemi Samuel Folorunso, Olihile M Sebolai
Aug 16, 2019·Science Translational Medicine·Virginia E PitzerNigel A Cunliffe
Nov 15, 2016·Future Virology·Eleanor BurnettUmesh D Parashar
Jun 16, 2019·The Lancet Global Health·Elizabeth T Rogawski McQuade, James A Platts-Mills
Mar 19, 2021·Journal of Clinical Microbiology·Melissa M CoughlinBettina Bankamp
Aug 23, 2020·The Lancet Global Health·Eleanor BurnettJacqueline E Tate
Nov 18, 2021·The Cochrane Database of Systematic Reviews·Hanna BergmanKarla Soares-Weiser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute viral rhinopharyngitis

Acute viral rhinopharyngitis, also known as "common cold", is an acute, self-limiting viral infection of the upper respiratory tract involving the nose, sinuses, pharynx and larynx. Discover the latest research on acute viral rhinopharyngitis here.